⌘K

13:14:49·77d

SECFilingvia Quantisnow

Amendment: SEC Form SCHEDULE 13G/A filed by Corbus Pharmaceuticals Holdings Inc.

ByQuantisnow·Wall Street's wire, on your screen.

CRBP· Corbus Pharmaceuticals Holdings Inc.

Health Care

Original source

Quantisnowquantisnow.com

Quantisnow streams SEC filings, FDA approvals, analyst ratings, insider trades, and press releases to retail investors in real time. This insight was curated and delivered from the Quantisnow live feed.

Companies

CRBP
Corbus Pharmaceuticals Holdings Inc.
Health Care

Recent analyst ratings

Jul 30UpdateB. Riley Securities$28.00
Feb 28UpdateWilliam Blair-
Dec 2UpdatePiper Sandler-
Jul 30UpdateWedbush$85.00
Jul 22UpdateH.C. Wainwright$80.00
Jun 26UpdateB. Riley Securities$85.00

Related

PR6d
Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701
SEC11d
SEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.
SEC11d
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
SEC14d
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
PR14d
Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity
SEC21d
Corbus Pharmaceuticals Holdings Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
PR21d
Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer
SEC25d
SEC Form DEFA14A filed by Corbus Pharmaceuticals Holdings Inc.